Home/Pipeline/APN401

APN401

Advanced Solid Tumors

Phase 1Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active

Company

invIOs

About invIOs

invIOs is a Vienna-based biotech developing novel immuno-oncology therapies, with a pipeline featuring both an autologous cell therapy platform (EPiC) and a small molecule program. Its lead asset, APN401, is in Phase 1 trials for solid tumors, while other programs target glioblastoma, AML, and enhanced CAR therapies. The company is privately held, raised a €8.2M Series A, and is led by a team with deep expertise in oncology drug development and Austrian biotech.

View full company profile

Therapeutic Areas

Oncology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active